LARGER THAN LIFE SCIENCE - Funding Now: Market Trends in 2022

Meet your fellow life science innovators! Get connected through a round of speed networking guided by MilliporeSigma. Enjoy beer and light refreshments courtesy of BioLabs NTX.

Today’s life science companies face tougher market conditions than we’ve seen in recent years. In Q1, VC investment was down, IPO activity was down and due diligence is taking longer. Many offerings have been put on hold as startups, investors and banks navigate this dramatic market shift.

Join us for the latest market intelligence for startups from Dr. Patrick Huddie, Partner at the Westbury Group with David Cary, First Vice President, Financial Advisor - Wealth Management at Morgan Stanley. This expert analysis will address the current market environment for public and private life science companies, the outlook for the next 12 months, and financing options for IPO-ready startups.

• Patrick Huddie, PhD, Partner, Westbury Group
• David A. Cary, Financial Advisor, First Vice President, Morgan Stanley Wealth Management

Get ready for round two of speed networking with MilliporeSigma

Startups have options when it comes to funding sources—and timing is key. Non-dilutive funding sources can supplement financing as a company progresses through stages of growth and can help lengthen the runway between venture rounds in today’s challenging market climate. Develop your funding strategy early and it will pay off in future rounds.

Learn from a team of funding professionals on the right time to engage and key elements to develop a cohesive early-stage funding strategy to leverage both non-dilutive and venture financing sources together to conserve capital and make it to your next milestone!

• Kelsey Haley, MA, Regional Director, CSC Leasing
• Annie Kadota, Sr. Vice President, Silicon Valley Bank

Event Venue & Nearby Stays

Pegasus Park | Biotech+, 3000 Pegasus Park Drive, Dallas, United States